Mannan-binding lectin plasma levels in leprosy: Deficiency confers protection against the lepromatous but not the tuberculoid forms

Clinical and Experimental Immunology

Volumn 145, Issue 3, 2006, Pages 463-468

  Dornelles, L N ^a   Pereira Ferrari, L ^a   Messias Reason, I ^a,b  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Complement; Leprosy; M. leprae; Mannan binding lectin

Indexed keywords

C REACTIVE PROTEIN; MANNAN BINDING LECTIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COMPLEMENT SYSTEM; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENZYME IMMUNOASSAY; ETHNIC GROUP; FEMALE; HOST RESISTANCE; HUMAN; INFECTION PREVENTION; INTERNALIZATION; LEPROMATOUS LEPROSY; LEPROSY; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM LEPRAE; NEPHELOMETRY; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX RATIO; TUBERCULOID LEPROSY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; LEPROSY; LEPROSY, LEPROMATOUS; LEPROSY, TUBERCULOID; MALE; MANNOSE-BINDING LECTIN; MIDDLE AGED; MYCOBACTERIUM LEPRAE; STATISTICS, NONPARAMETRIC;

EID: 33747408991     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2006.03161.x     Document Type: Article

References (31)

1. World Health Organization. Global leprosy situation. Weekly Epidemiological Record 2005; 80:285-96. [http://www.who.int/Lep/]
2. Britton WJ, Lockwood DNJ. Leprosy. Lancet 2004; 363:1209-19.
3. Goulart IMB, Penna GO, Cunha G. Immunopathology of Leprosy: the complexity of the mechanisms of host immune response to Mycobacterium leprae. Rev Soc Bras Med Trop 2002; 35:365-75.
4. Alcaïs A, Mira M, Casanova JL et al. Genetic dissection of immunity in leprosy. Curr Opin Immunol 2005; 17:44-8.
5. Araújo MG. Leprosy in Brazil. Rev Soc Bras Med Trop 2003; 36:373-82.
6. Jack DL, Klein N, Turner MW. Mannose-binding lectin: targeting the microbial world for complement attack and opsonophagocytosis. Immunol Rev 2001; 180:86-99.
7. Turner MW. The role of mannose-binding lectin in health and disease. Mol Immunol 2003; 40:423-9.
8. Casanova JL, Abel L. Human mannose-binding lectin in immunity: friend, foe, or both? J Exp Med 2004; 199:1295-9.
9. Grayholt CH, Leth-Larsen R, Lauridsen AL et al. The effects of GH and hormone replacement therapy on serum concentrations of mannan-binding lectin, surfactant protein D and vitamin D binding protein in Turner syndrome. Eur J Endocrinol 2004; 150:355-62.
10. Thiel S, Holmskov U, Hviid L et al. The concentration of the Ctype lectin, mannan-binding protein, in human plasma increases during an acute phase response. Clin Exp Immunol 1992; 90:31-5.
11. Summerfield JA, Ryder S, Sumiya M et al. Mannose binding protein gene mutations associated with unusual and severe infections in adults. Lancet 1995; 345:886-9.
12. Summerfield JA, Sumiya M, Levin M et al. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. BMJ 1997; 314:1229-32.
13. Super M, Thiel S, Lu J et al. Association of low levels of mannan-binding protein with a common defect of opsonization. Lancet 1989; 2:1236-9.
14. Turner MW. Deficiency of mannan binding protein - a new complement deficiency syndrome. Clin Exp Immunol 1991; 86:53-6.
15. Garred P, Harboe M, Oettinger T et al. Dual role of mannan-binding protein in infections: another case of heterosis? Eur J Immunogenet 1994; 21:125-31.
16. Bonar A, Chmiela M, Rudnicka W et al. Mannose-binding lectin enhances the attachment and phagocytosis of mycobacteria in vitro. Arch Immunol Ther Exp 2005; 53:437-41.
17. Madsen HO, Satz ML, Hogh B et al. Different molecular events result in low protein levels of mannan-binding lectin in populations from Southeast Africa and South America. J Immunol 1998; 161:3169-75.
18. Soborg C, Madsen HO, Andersen AB et al. Mannose-binding lectin polymorphisms in clinical tuberculosis. J Infect Dis 2003; 188:777-82.
19. Ridley DS, Jopling WH. Classification of leprosy according to immunity: a five group system. Int J Lepr 1966; 34:255-73.
20. Bleharski JR, Li H, Meinken C et al. Use of genetic profiling in leprosy to discriminate clinical forms of the disease. Science 2003; 301:1527-30.
21. Remus N, Alcaïs A, Abel L. Human genetics of common Mycobacterium infections. Immunol Res 2003; 28 (2):109-29.
22. Messias IJT, Santamaria J, Brenden M et al. Association of C4B deficiency (C4B*Q0) with erythema nodosum in leprosy. Clin Exp Immunol 1993; 92:284-7.
23. Kilpatrick DC. Mannan-binding lectin. clinical significance and applications. Biochim Biophy Acta 2002; 1572:104-13.
24. Eisen DP, Minchinton RM. Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin Infect Dis 2003; 37:1496-505.
25. Fiane AE, Ueland T, Simonsen S et al. Low mannose-binding and increased complement activation correlate to allograft vasculopathy, ischaemia, and rejection after human heart transplantation. Eur Heart J 2005; 26:1660-5.
26. Ambrosio AR, Messias-Reason IJ. Leishmania (Viannia) braziliensis: interaction of mannose-binding lectin with surface glycoconjugates and complement activation. An antibody-independent defense mechanism. Parasite Immunol 2005; 27:333-40.
27. Mira MT. Genetic host resistance and susceptibility to leprosy. Microbes Infect 2006; 8:1124-31.
28. Takahashi K, Gordon J, Liu H et al. Lack of mannose-binding lectin-A enhances survival in a mouse model of acute septic peritonitis. Microbes Infect 2002; 4:773-84.
29. Bonar A, Chmiela M, Rozalska B. Levels of mannose-binding lectin (MBL) in patients with tuberculosis. Pneumonol Alergol Pol (Pneumonologia Polska) 2004; 72:201-5.
30. Ezekowit RAB, Day LE, Herman GAA. Human mannose-binding protein is an acute-phase reactant that shares sequence homology with other vertebrate lectins. J Exp Med 1988; 167:1034-46.
31. Taylor M, Brickell PM, Craig RK et al. Structure and evolutionary origin of the gene encoding a human serum mannose-binding protein. Biochem J 1989; 262:736-71.